Bioengineered Prostate-on Chip: Mechanisms of Stromal Dysregulation in Prostate Cancer
生物工程前列腺芯片:前列腺癌基质失调的机制
基本信息
- 批准号:10386865
- 负责人:
- 金额:$ 47.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-07 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AR geneAddressAgeAllyAndrogen ReceptorBasal CellBiological TestingBiologyBiomedical EngineeringCell Differentiation processCell LineCell MaintenanceCell SurvivalCellsCoculture TechniquesDataDependenceDevelopmentDiagnosisDiseaseDuct (organ) structureEpithelialEpithelial CellsFGF10 geneFibroblastsGenetic TranscriptionGlandHumanIn SituIndividualMAP3K7 geneMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMediatingMicrofluidic MicrochipsModelingNOTCH3 geneOncogenesOncogenicOrangesPatientsPhenotypePhysiologicalProstateReceptor SignalingRepressionSignal TransductionStratified EpitheliumStromal CellsStructureTNF geneTestingTissuesTransforming Growth Factor betaTranslationsTumor Cell LineTumor-Derivedanticancer researchbasecancer cellcarcinogenesishost neoplasm interactionhuman modelin vivomanmenmorphogensneoplastic cellnew technologyoverexpressionpreservationprostate cancer modelreceptor expressiontumortumorigenesistumorigenic
项目摘要
ABSTRACT
It is well accepted that intrinsic action of the androgen receptor (AR) within the prostate epithelium drives prostate
cancer proliferation and survival. Less appreciated is the fact that AR is also expressed in the stroma surrounding
the epithelium. Stromal-expressed AR acts extrinsically to maintain the differentiated striated basal and luminal
epithelium of the normal gland. During prostate cancer development, AR expression in the stroma is lost. How
AR is lost from the stroma and how its loss promotes prostate cancer development is unknown. Our objectives
are to define the mechanism that leads to stromal-specific AR loss and determine how AR loss in the stroma, in
conjunction with epithelial oncogenesis, promotes prostate cancer development Based on our preliminary data,
we hypothesize that tumor-derived TNFα/TGFβ1 transcriptionally suppresses AR expression in the stroma,
causing loss of FGF10 and Wnt16 secretion, which are required to maintain the stratified epithelium through
induction of luminal cells and maintenance of basal cells, respectively. To test this, we developed the first human
Prostate-on-Chip model by culturing basal epithelial cells next to prostate stromal cells within a microfluidic
device. Within this model, we can fully recapitulate the stromal AR-dependent induction of luminal epithelial cell
differentiation. Furthermore, co-culturing normal stroma with tumor cells within this model leads to the induction
of CAF phenotypes and reduced stromal AR expression, mimicking the tumor/host interactions seen in vivo.
Models that recapitulate human glandular organization and its dysregulation during disease development are
critical for our mechanistic understanding of how stroma and oncogenic epithelial interactions drive tumor
development. We will test our hypothesis in three aims: 1) Determine the mechanism by which stromal AR
maintains prostate epithelial cell differentiation. Our working hypothesis is that stromal AR signaling induces
secretion of stromal FGF10 and Wnt16, which are required for induction of luminal epithelial cells and
maintenance of basal epithelial cells, respectively. 2) Determine the mechanism by which AR expression is lost
in the tumor stroma. Our working hypothesis is that tumor-secreted factors, TNFα and TGFβ1, acting through
NF-κB signaling, suppress transcription of the stromal AR gene independent of CAF conversion. 3) Determine
the functional consequence of tumor-induced stromal AR loss on prostate epithelial differentiation in a new de
novo in situ human prostate cancer model. Our working hypothesis is that tumor-induced stromal loss of AR-
dependent induction of Wnt16 and FGF10, via TNFα/TGFβ1, co-operates with epithelial oncogenes to accelerate
tumor development and induce loss of basal epithelial cells. The proposed studies will be the first to demonstrate
how TNFα/TGFβ-mediated suppression of stromal AR expression leads to the loss of Wnt16 and FGF10 to
promote prostate cancer development. These studies will also provide the framework for further development of
the first human Prostate-on-Chip model, which recapitulates human prostate biology, for basic and translation
cancer research.
摘要
众所周知,前列腺上皮内雄激素受体(AR)的内在作用驱动前列腺增生,
癌细胞增殖和存活。不太了解的是,AR也表达在周围的基质中,
上皮细胞间质表达的AR在细胞外起作用,维持分化的纹状体基底和管腔
正常腺体的上皮。在前列腺癌发展过程中,基质中的AR表达丢失。如何
AR从基质中丢失,其丢失如何促进前列腺癌的发展尚不清楚。我们的目标
是为了确定导致基质特异性AR损失的机制,并确定基质中的AR损失,
结合上皮肿瘤发生,促进前列腺癌的发展基于我们的初步数据,
我们假设肿瘤源性TNFα/TGFβ1在转录上抑制间质中的AR表达,
导致FGF 10和Wnt 16分泌的损失,所述FGF 10和Wnt 16分泌是维持复层上皮细胞所需的,
分别诱导腔细胞和维持基底细胞。为了验证这一点,我们开发了第一个人类
通过在微流体内培养邻近前列腺基质细胞的基底上皮细胞的前列腺芯片模型
设备.在这个模型中,我们可以完全概括间质AR依赖性的管腔上皮细胞诱导,
分化此外,在该模型中,将正常基质与肿瘤细胞共培养导致诱导
CAF表型和减少的基质AR表达,模拟体内观察到的肿瘤/宿主相互作用。
概括人类腺体组织及其在疾病发展过程中失调的模型是
对于我们理解基质和致癌上皮相互作用如何驱动肿瘤的机制至关重要
发展我们将从三个方面检验我们的假设:1)确定基质AR
维持前列腺上皮细胞分化。我们的工作假设是间质AR信号诱导
分泌基质FGF 10和Wnt 16,它们是诱导腔上皮细胞所需的,
分别维持基底上皮细胞。2)确定AR表达丢失的机制
在肿瘤间质中。我们的工作假设是,肿瘤分泌因子TNFα和TGFβ1通过
NF-κB信号传导抑制不依赖于CAF转化的基质AR基因的转录。3)确定
肿瘤诱导的间质AR缺失对前列腺上皮分化的功能影响
新的原位人前列腺癌模型。我们的工作假设是肿瘤诱导的AR-
通过TNFα/TGFβ1对Wnt 16和FGF 10的依赖性诱导,与上皮癌基因协同作用,
肿瘤发展并诱导基底上皮细胞的损失。拟议中的研究将首次证明
TNFα/TGFβ介导的间质AR表达抑制如何导致Wnt 16和FGF 10的丢失,
促进前列腺癌的发展。这些研究还将为进一步发展
第一个人类前列腺芯片模型,它概括了人类前列腺生物学,用于基础和翻译
癌症研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cynthia K Miranti其他文献
Cynthia K Miranti的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cynthia K Miranti', 18)}}的其他基金
Bioengineered Prostate-on Chip: Mechanisms of Stromal Dysregulation in Prostate Cancer
生物工程前列腺芯片:前列腺癌基质失调的机制
- 批准号:
10593937 - 财政年份:2021
- 资助金额:
$ 47.21万 - 项目类别:
Bioengineered Prostate-on Chip: Mechanisms of Stromal Dysregulation in Prostate Cancer
生物工程前列腺芯片:前列腺癌基质失调的机制
- 批准号:
10204253 - 财政年份:2021
- 资助金额:
$ 47.21万 - 项目类别:
Role of alpha6 beta1 Integrin in Prostate Cancer
α6β1整合素在前列腺癌中的作用
- 批准号:
8464670 - 财政年份:2012
- 资助金额:
$ 47.21万 - 项目类别:
Role of alpha6 beta1 Integrin in Prostate Cancer
α6β1整合素在前列腺癌中的作用
- 批准号:
8292638 - 财政年份:2012
- 资助金额:
$ 47.21万 - 项目类别:
Tyrosine Kinase Signaling in Cancer, Disease, & Development
癌症、疾病中的酪氨酸激酶信号传导,
- 批准号:
8398049 - 财政年份:2012
- 资助金额:
$ 47.21万 - 项目类别:
Role of alpha6 beta1 Integrin in Prostate Cancer
α6β1整合素在前列腺癌中的作用
- 批准号:
8665532 - 财政年份:2012
- 资助金额:
$ 47.21万 - 项目类别:
Role of alpha6 beta1 Integrin in Prostate Cancer
α6β1整合素在前列腺癌中的作用
- 批准号:
8627582 - 财政年份:2012
- 资助金额:
$ 47.21万 - 项目类别:
Role of alpha6 beta1 Integrin in Prostate Cancer
α6β1整合素在前列腺癌中的作用
- 批准号:
9024459 - 财政年份:2012
- 资助金额:
$ 47.21万 - 项目类别:
PROTEIN KINASE C AND INTEGRIN MEDIATED SIGNALING
蛋白激酶 C 和整合素介导的信号传导
- 批准号:
2769893 - 财政年份:1998
- 资助金额:
$ 47.21万 - 项目类别:
PROTEIN KINASE C AND INTEGRIN MEDIATED SIGNALING
蛋白激酶 C 和整合素介导的信号传导
- 批准号:
2115590 - 财政年份:1997
- 资助金额:
$ 47.21万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 47.21万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 47.21万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 47.21万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 47.21万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 47.21万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 47.21万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 47.21万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 47.21万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 47.21万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 47.21万 - 项目类别:
Research Grant














{{item.name}}会员




